Evidence map›Paper›PMID 34951678›Full record

ArticleAdvances in therapy2022

Individualized HbA

Dominik Lautsch, Robert Boggs, Tongtong Wang, Claudio Gonzalez, Gary Milligan, Swapnil Rajpathak, Seema Malkani, Euan McLeod, James Carroll, Victoria Higgins

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Additive Effects of Quercetin-RichPharmaceuticals (Basel, Switzerland) · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Dominik LautschMerck & Co., Inc, Kenilworth, NJ, USA.
Robert BoggsMerck & Co., Inc, Kenilworth, NJ, USA.ORCID http://orcid.org/0000-0003-1309-0650
Tongtong WangMerck & Co., Inc, Kenilworth, NJ, USA.
Claudio GonzalezMerck & Co., Inc, Kenilworth, NJ, USA.
Gary MilliganAdelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, Cheshire, UK.ORCID http://orcid.org/0000-0002-1427-3339
Swapnil RajpathakMerck & Co., Inc, Kenilworth, NJ, USA.
Seema MalkaniMerck & Co., Inc, Kenilworth, NJ, USA.
Euan McLeodPfizer Ltd, Tadworth, UK.
James CarrollAdelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, Cheshire, UK.ORCID http://orcid.org/0000-0002-6398-0902
Victoria HigginsAdelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, Cheshire, UK. Victoria.Higgins@adelphigroup.com.ORCID http://orcid.org/0000-0002-3901-7390
Merck & Co., Inc., Rahway, NJ, USA (United States) · USAdelphi Group (United Kingdom) · GBPfizer (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWhile glycemic control is key in effective type 2 diabetes mellitus management, many patients fail to reach their individualized glycemic goal. This analysis aimed to describe a real-world picture of diabetes management: individualized hemoglobin A

methodsAnalysis of physicians and the next ten consulting patients with type 2 diabetes mellitus conducted in Europe and the USA including medical record data abstraction/assessment by physicians, a patient-reported survey and a physician survey. Patients were diagnosed for 3 months or more with a known current and target HbA

resultsA total of 730 physicians provided data on 8794 patients with type 2 diabetes mellitus; 5331 patients were eligible for this analysis. Overall, mean (standard deviation, SD) individualized HbA

conclusionsOur results showed that the proportion of patients with type 2 diabetes mellitus achieving their goals for glycemic control was suboptimal when compared to current guideline criteria, with only about 40% of patients achieving their individualized HbA

Indexed as

Diabetes Mellitus, Type 2GoalsBlood GlucoseGlycated HemoglobinHumansHypoglycemic AgentsSurveys and QuestionnairesBlood GlucoseGlycated HemoglobinHypoglycemic AgentsGlycemic controlGlycemic goal attainmentIndividualized HbA1cIndividualized HbA1c goalIndividualized HbA1c targetPatient goal awarenessPatient target awarenessReal worldType 2 diabetes mellitus

Identifiers

PMID34951678
PMCPMC8706771
OpenAlexW4200197703

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.